About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

UK's State-funded Health Service Denies Life-saving Treatment to Six Children

by Vishnuprasad on October 19, 2015 at 7:14 PM
Font : A-A+

UK's State-funded Health Service Denies Life-saving Treatment to Six Children

The United Kingdom's state-funded health service has denied life-saving treatment to a 6-year-old Indian-origin boy and five other children.

Kirath Mann suffers from Duchenne muscular dystrophy (DMD), which affects one in 3,500 boys in Britain and leaves many in a wheelchair before their 10th birthday.

Advertisement

His family, from Coventry in the West Midlands region of England, joined forces with other families to campaign to end delays to a breakthrough treatment called Translarna but failed due to high expenses involved.

"We are devastated at having to face yet more disappointment after another hurdle has been put in our way. All these organizations and National Health Service (NHS) bodies that have been involved in the decision do not seem to be appreciative that this is a rare disease and very progressive one as well," Kirath's mother Jaspal told 'The Coventry Telegraph'.
Advertisement

Kirath and five other boys with the condition even wrote personal letters to British Prime Minister David Cameron in June in a bid to get the drug that could save their lives.

The National Institute for Health and Care Excellence (NICE), which decides on commissioning new drugs for the NHS, has decided that drug manufacturers PCT Therapeutics need to present more information on the benefits of the drug to coincide with the cost as Translana can cost up to 4,00,000 pounds per patient a year.

"It was at NICE's discretion to give a positive decision and it was in their remit to do that. But they decided to go for a different approach," she added.

The drug - also known as Ataluren - is the first-ever to tackle the causes of DMD and was approved in Europe in August last year and is available in France, Spain, Germany, Italy and Denmark, but not in the UK.

"We are disappointed not to be able to recommend Ataluren in this draft guidance. After considering the evidence, and the opinions of the clinical and patient experts, the Committee agreed that Ataluren represents an important development in the treatment of DMD."

"It could potentially prolong the time before children have to use a wheelchair, compared with best supportive care," said Prof Carole Longson, NICE health technology evaluation center director.



Source: PTI
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Child Health News

 List of Do's and Don'ts for Vaccination in Infants
What precautions should be taken after vaccination in newborn? Check out some essential dos and don'ts of vaccinating to make informed decisions about their health.
 Virtual Reality Exploring Brain Structure Changes in Autism
Virtual reality-based imaging system provides crucial information to understand dynamics of brain network linked to behavioral abnormality of autism.
Practical Tips for Defending Against the H3N2 Virus!
Doctors have reported that children have been hit hard by the recent increase in flu cases, with the H3N2 virus being a significant contributing factor.
Breaking the Cycle: Impact of Childhood Trauma on Mental Health
Men and women are impacted uniquely by childhood trauma: emotional trauma and sexual abuse impact women, while emotional and physical neglect impact men.
How Can Parents Manage Night-Time Breastfeeding in Young Infants?
Bedsharing with infants is linked to increased duration of breastfeeding, according to the night-time feeding guidelines.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

UK's State-funded Health Service Denies Life-saving Treatment to Six Children Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests